S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Precigen, Inc. Common Stock

PGEN XNAS
$7.23 +0.31 (+4.49%) ▲ 15-min delayed
Open
$7.05
High
$7.26
Low
$6.93
Volume
5.76M
Market Cap
$2.47B

About Precigen, Inc. Common Stock

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 47 Website →

Key Financials

Period Revenue Net Income EPS
Q2 2026 $54.98M $20.07M $0.06
Q1 2026 $23.25M $-7,929,000 $-0.02
FY 2025 $9.68M $-250,642,000 $-1.37
Q3 2025 N/A $-146,344,000 $-1.06

Related Market News

No specific coverage for PGEN yet. Check out our latest market news or earnings calendar.

Get PGEN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Precigen, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.